NMI 8000

Drug Profile

NMI 8000

Alternative Names: Mullerian inhibitory substance - Nemucore; NMI-8000; rhMIS - Nemucore

Latest Information Update: 17 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Massachusetts General Hospital; Nemucore Medical Innovations
  • Developer Massachusetts General Hospital; Nemucore Medical Innovations; Pfenex
  • Class Proteins; Transforming growth factors
  • Mechanism of Action Anti-Mullerian hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gynaecological cancer; Ovarian cancer

Most Recent Events

  • 14 Dec 2015 Nemucore Medical Innovations in-licenses Expression Technology® for the production of NMI 8000 from Pfenex
  • 09 Dec 2015 Preclinical trials in Gynaecological cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top